Keyword: Allergan

President Trump convinced one pharma giant to retreat on price increases, and it’s not good news for other price-hiking drugmakers.

Dermira's nod for problem perspiration fighter Qbrexza hit as the company’s awareness push was already drawing in consumers.

J&J and Allergan are among the pharma companies mulling both acquisitions and selloffs, signaling that the M&A boom will continue through 2018.

J&J's retiring Group Worldwide Chair Sandra Peterson, with $17.18 million in 2017 compensation, was the top-paid female biopharma exec.

Achaogen shares slipped Tuesday after the FDA slapped brand-new Zemdri with a black-box warning and nixed a second indication it hoped to gain.

Allergan is in the middle of making some moves to revive its struggling shares. And the success of its pipeline could dictate its next moves, analysts say.

Allergan is keeping the birth control questions coming—this time in a quiz format.

Rebel investors earlier this month called for changes at Allergan, and now the company has appointed a new director.

When it comes to celebrity firepower, there’s no drugmaker like Allergan. And it’s giving that treatment to its Alzheimer's caregivers campaign.

Some Allergan shareholders reportedly have a former insider in mind for the chairman's role: David Pyott, who led the company until its buyout in 2015.